MRVI vs SGP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MRVI · Maravai LifeSciences$7.52 ▲ 7.74%
SGP · SpyGlass Pharma$36.95 ▲ 8.41%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MRVI +139.5%
- SGP +40.0%
Head to head
| Metric | MRVI | SGP |
|---|---|---|
| Price | $7.52 | $36.95 |
| Change today | ▲ 7.74% | ▲ 8.41% |
| Market cap | $1.12B | $1.24B |
| Return, 3 months | +23.9% | +46.8% |
| Return, year to date | +131.4% | – |
| Return, 1 year | +162.0% | – |
| P/E (TTM) | -17.1 | -22.0 |
| P/B | 5.7 | 5.3 |
| P/E percentile vs own 5y | 1st | 25th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +8.5% | – |
| Net profit growth (YoY) | +69.0% | -129.0% |
| Gross margin | 34.9% | – |
| Operating margin | -33.7% | – |
| Net margin | -37.1% | – |
| Return on equity | -32.9% | -24.1% |
| Analyst target vs. price | +4.1% | +6.5% |
| Analyst buy share | 80% | 100% |
| RSI (14) | 51 | 80 |
| 30-day volatility | 87.4% | 56.3% |
| Max drawdown, 1 year | -29.6% | -40.8% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SGP is the largest of the group by market value.
- SGP carries the lowest trailing P/E.
- SGP has been the calmest stock over the last 30 days.